Serum of India says 40 million doses of AstraZeneca’s COVID vaccine to make Novaxax soon

BENGALURU (Reuters) – The world’s largest vaccine-producing serum Institute of India said on Thursday that it had made a 40 million dose of AstraZeneca’s potential COVID-19 vaccine, and would soon begin making rival shots of Novaxax, as They both seek regulatory approval.

Although no COVID-19 vaccines have been approved yet and testing is still underway funded to begin production to deliver early delivery to leading drugmakers to prove that they are safe and effective, Because the epidemic has killed more than 1.2 million people worldwide.

AstraZeneca AZN.L Last week it said it was withdrawing delivery of its COVID-19 vaccine candidate while it was awaiting data from late-stage clinical trials, which were delayed due to heat in UK coronovirus infections.

Serum declined to comment on whether the 40 million doses of the AstraZeneca vaccine were for global supply or for India only.

For the production of Novavax NVAX.O The vaccine, Serum, said it received the bulk of the vaccine from an American company and will soon fill and eliminate them in vials.

Novavax, which is testing its vaccine in a late-stage study in the UK, last month postponed its US trial start for a month due to delays in extending the manufacturing process.

Serum said it had enrolled 1,600 participants in India for AstraZeneca candidate final-stage trials, and also plans to seek regulatory approval to run late-stage trials for the Novavax vaccine.

The AstraZeneca vaccine, co-developed by the University of Oxford, is the most advanced in human testing in India, Serum said, adding that the company and the Indian Council of Medical Research (ICMR) will pursue the shot’s “early availability” in India.

A federal government body, ICMR, funded the clinical trial site fee for the AstraZeneca vaccine, Serum said. The company and ICMR are currently conducting Phase 2/3 clinical trials in 15 centers across India.

The news came in India in the form of a coronovirus infection, the world’s second-worst hit country, reaching 8.68 million on Thursday and the death toll rose to over 128,000.

There are at least two home-grown COVID-19 vaccine candidates in development in India, while local drug manufacturer Drs. Reddy’s Labs REDY.NS Russia is conducting a test in the country for the vaccine candidate.

Earlier this week, Pfizer PFE.N And its partner BioNTech 22UAy.DE Said that their vaccine candidates were proven to be more than 90% effective based on preliminary test results. Pfizer said it is committed to furthering its engagement with the Indian government to supply its potential vaccine in the country.

Reporting by Sachin Ravikumar; Editing by Miang Kim and Michael Perry


Leave a Reply

Your email address will not be published.